SCHEMBL15536895

SCHEMBL15536895

Clc1cccc(C(Cl)c2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 1/20 0.52
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
TSHR P16473 2/20 0.44
OPRM1 P35372 3/20 0.41
OPRD1 P41143 3/20 0.41
OPRK1 P41145 3/20 0.41
OPRL1 P41146 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
LMNA P02545 3/20 0.41
MAPT P10636 2/20 0.41
HTT P42858 2/20 0.41
IDO1 P14902 2/20 0.41
TDO2 P48775 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
CASR P41180 1/20 0.41
ALPL P05186 1/20 0.41
ALPI P09923 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29712699 0.93 ACP3 (0.47) ACP3MEN1KMT2ATSHROPRM1
SCHEMBL11614094 0.93 ACP3 (0.47) ACP3MEN1KMT2ATSHROPRM1
SCHEMBL11642692 0.90 CYP1A2 (0.45) ACP3MEN1KMT2ATSHRNPC1
SCHEMBL4375119 0.81 ACP3 (0.50) ACP3MEN1KMT2ATSHROPRM1
SCHEMBL151375 0.80 TSHR (0.65) TSHRALDH1A1HPGDLMNARAB9A
SCHEMBL1573848 0.78 IDO1 (0.56) TSHRHPGDLMNAMAPTIDO1
SCHEMBL5318844 0.78 TSHR (0.50) ACP3MEN1KMT2ATSHROPRM1
Hydrogen Sulfide SCHEMBL21379318 0.77 TSHR (0.61) TSHRALDH1A1HPGDLMNARAB9A
Bromide SCHEMBL21831069 0.77 TSHR (0.61) TSHRALDH1A1HPGDLMNARAB9A
SCHEMBL11820501 0.77 TSHR (0.61) TSHRALDH1A1HPGDLMNAIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2855428-A1 N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN Genentech, Inc. (US) 2015-04-08 EP disclosed
US-8952169-B2 N-substituted benzamides and methods of use thereof XENON PHARMACEUTICALS INC. (CA) 2015-02-10 US disclosed
US-8952169-B2 N-substituted benzamides and methods of use thereof XENON PHARMACEUTICALS INC. (CA) 2015-02-10 US disclosed
WO-2013177224-A1 N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN GENENTECH, INC. (US) 2013-11-28 WO disclosed
US-20090182057-A1 DEUTERATED AMINOGLYCIDAL COMPOUNDS AUSPEX PHARMACEUTICALS, INC. (US) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182057-A1 DEUTERATED AMINOGLYCIDAL COMPOUNDS ADRB2, GLRB, ADRB1 ACP3 4642/4885MEN1 2002/4885KMT2A 3732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.